reviewNature Reviews Drug DiscoveryApr 30, 2012Closed access

Bench to bedside: elucidation of the OPG–RANK–RANKL pathway and the development of denosumab

DLDavid L. LaceyWJWilliam J. BoyleWSW. Scott SimonetPJPaul J. KostenuikWCWilliam C. Dougall

Amgen (United States) · Ciência Viva · +1 more institution

PubMed
Indexed incrossrefpubmed

Abstract

No abstract available for this paper.

Citation impact

679
total citations
FWCI
18.14
Percentile
100%
References
152
Citations per year

Authors

8

Topics & keywords

Topics
Keywords
  • RANKL
  • Denosumab
  • Osteoprotegerin
  • Osteoclast
  • Bone resorption
  • RANK Ligand
  • Medicine
  • Osteoblast
UN Sustainable Development Goals
  • Zero hunger
No related works found for this paper.